Our top pick for
TransAtlantic Petroleum Ltd is an oil & gas e&p business based in the US. TransAtlantic Petroleum shares (TAT) are listed on the NYSE MKT and all prices are listed in US Dollars. TransAtlantic Petroleum employs 147 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.20 - $0.31|
|50-day moving average||$0.26|
|200-day moving average||$0.26|
|Wall St. target price||$1.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing TransAtlantic Petroleum stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransAtlantic Petroleum's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TransAtlantic Petroleum's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 million.
The EBITDA is a measure of a TransAtlantic Petroleum's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$40 million|
|Gross profit TTM||$51.2 million|
|Return on assets TTM||-7.65%|
|Return on equity TTM||-90.35%|
|Market capitalisation||$18.6 million|
TTM: trailing 12 months
There are currently 3.4 million TransAtlantic Petroleum shares held short by investors – that's known as TransAtlantic Petroleum's "short interest". This figure is 0.2% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting TransAtlantic Petroleum shares can be evaluated.
TransAtlantic Petroleum's "short interest ratio" (SIR) is the quantity of TransAtlantic Petroleum shares currently shorted divided by the average quantity of TransAtlantic Petroleum shares traded daily (recently around 1.6 million). TransAtlantic Petroleum's SIR currently stands at 2.1. In other words for every 100,000 TransAtlantic Petroleum shares traded daily on the market, roughly 2100 shares are currently held short.
However TransAtlantic Petroleum's short interest can also be evaluated against the total number of TransAtlantic Petroleum shares, or, against the total number of tradable TransAtlantic Petroleum shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TransAtlantic Petroleum's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 TransAtlantic Petroleum shares in existence, roughly 40 shares are currently held short) or 0.0585% of the tradable shares (for every 100,000 tradable TransAtlantic Petroleum shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TransAtlantic Petroleum.
Find out more about how you can short TransAtlantic Petroleum stock.
We're not expecting TransAtlantic Petroleum to pay a dividend over the next 12 months.
TransAtlantic Petroleum's shares were split on a 1:10 basis on 6 March 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TransAtlantic Petroleum shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for TransAtlantic Petroleum shares which in turn could have impacted TransAtlantic Petroleum's share price.
Over the last 12 months, TransAtlantic Petroleum's shares have ranged in value from as little as $0.2 up to $0.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while TransAtlantic Petroleum's is 1.3207. This would suggest that TransAtlantic Petroleum's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TransAtlantic Petroleum Ltd. , an oil and natural gas company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in Turkey and Bulgaria. As of December 31, 2019, it had interests in 4 onshore exploration licenses and 20 onshore production leases covering an area of 436,388 net acres with a total net proved reserves of 10,259 thousand barrels of oil and 2,466 million cubic feet of natural gas located in Turkey, as well as a production concession covering an area of approximately 162,800 net undeveloped acres located in Bulgaria. The company was incorporated in 1985 and is based in Addison, Texas. As of December 18, 2020, TransAtlantic Petroleum Ltd. was taken private. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.